A current 24-week randomized, double-blind, placebo-controlled clinical trial is investigating the efficacy and safety of an inhaled sGC stimulator in improving exercise capacity for adults with COPD-related PH (Merck and Dohme, 2023). Here, SGCB is linked to chronic obstructive pulmonary disease.